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ABSTRACT: Biological signaling pathways are underpinned by
protein switches that sense and respond to molecular inputs.
Inspired by nature, engineered protein switches have been
designed to directly transduce analyte binding into a quantitative
signal in a simple, wash-free, homogeneous assay format. As such,
they offer great potential to underpin point-of-need diagnostics
that are needed across broad sectors to improve access, costs, and
speed compared to laboratory assays. Despite this, protein switch
assays are not yet in routine diagnostic use, and a number of
barriers to uptake must be overcome to realize this potential. Here, we review the opportunities and challenges in engineering
protein switches for rapid diagnostic tests. We evaluate how their design, comprising a recognition element, reporter, and switching
mechanism, relates to performance and identify areas for improvement to guide further optimization. Recent modular switches that
enable new analytes to be targeted without redesign are crucial to ensure robust and efficient development processes. The
importance of translational steps toward practical implementation, including integration into a user-friendly device and thorough
assay validation, is also discussed.
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Point-of-care and in-field tests are needed across broadsectors, in order to improve access, costs, and speed
compared to laboratory assays.1−5 The COVID-19 pandemic
highlights the real strength of rapid diagnostics to break
transmission and guide timely treatment in infectious disease
management,6−8 and the transformational power of fast on-site
results is evident across wide diagnostic applications.1,3,9
However, the need for quality has been acutely reinforced,
and in all sectors robust underpinning technology is required
to provide sufficient sensitivity, specificity, and reproducibility
in an easy-to-use format with a fast time-to-result.10,11
Inspiration can be taken from nature, where signaling is
underpinned by protein switches that sense and respond to
molecular inputs.12 Engineered protein switches have been
designed for synthetic biology and sensing applications and
could be transformational as a rapid alternative to laboratory
immunoassays.13−16 Immunoassays typically utilize separate
reagents for analyte recognition and signal generation,
necessitating multiple immobilization and wash steps that
prohibit direct point-of-need use (Figure 1A).17 Microfluidic
lab-on-a-chip systems can automate the steps, but few, like the
Abbott iSTAT point-of-care analyzer, have been commercially
successful.18 Lateral flow devices (LFDs) are the dominant
rapid test format in this market, offering a simple, cheap
solution by employing the molecular recognition and reporter
components on a single test strip (Figure 1B).19 However, they
are often only semiquantitative and insufficiently sensitive for
many applications.19 To overcome such shortcomings,
engineered protein switches combine recognition and reporter
elements at the molecular level and directly transduce analyte
binding to an amplifiable, quantitative signal in a simple, wash-
free, homogeneous assay format (Figure 1C).13,14 They offer
great promise to underpin point-of-need tests, compared to
current homogeneous assays using chemiluminescent (e.g.,
AlphaLISA, SPARCL) or TR-FRET technology, which require
sophisticated equipment and are better suited to high-
throughput settings.20−22
Protein switches are well-established tools for lab-based
cellular assays and imaging, including widely used commercial
examples like protein-fragment complementation assays.23,24
Despite clear potential, the development of protein switches
for in vitro diagnostic assays is less mature, and while ever-
improving designs are reported,25−27 they are yet to be
established in routine diagnostic use. Here, we review the
opportunities and challenges for implementation of this
technology and offer prospective solutions by analyzing the
relationship between emerging protein switch designs and their
performance. Following a comprehensive review of protein
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switches in 2015,14 our focus is on developments from the past
5 years.
■ DESIGN AND PERFORMANCE
While the conceptual simplicity of protein switch assays offers
great potential, devising a design which retains the crucial
performance qualities of a laboratory immunoassay remains a
significant challenge. Exact specifications are application
dependent, but key assay performance characteristics include
sensitivity, selectivity, range, reproducibility, functionality in
biological matrices, and speed to results. A number of practical
considerations including costs, ease of manufacture, shelf life,
and ability to multiplex should also be favorable. It must also
be understood that despite their limitations the continuing
success of ELISAs and LFDs can be attributed to their highly
modular format, in which the recognition and reporter
components are simply exchanged to develop new assays.19,28
Recent efforts toward modular protein switch designs are
crucial if widespread adoption is to be achieved,29,30 so
development costs and times are competitive with LFDs, while
offering improvements in assay performance.
A wealth of protein switch designs have been proposed, each
with their own advantages and disadvantages for a particular
diagnostic application. Designs can be two-component
(proximity switches) or one-component (allosteric switches),
but they all transduce analyte binding at a recognition element
into activation of a reporter for signal generation (Figure 2).14
Proximity switches use colocalization of reporter components
for activation, whereas allosteric switches utilize a conforma-
tional change.14 Allosteric coupling between the recognition
and reporter elements can be achieved by direct domain
insertion or modular approaches that limit conformational
change to linker regions.14 The recognition element, reporter,
and switching mechanism all impact the performance
according to their designs. Understanding these relationships
is critical for optimizing protein switches toward the quality
standards laid out above but studies analyzing how incremental
changes in design parameters affect performance are somewhat
lacking in this application driven field. Thus, we will critically
review protein switch architectures and evidence our opinion
on how designs relate to key performance characteristics, to
improve the understanding of structure−function relationships,
identify areas for improvement, and guide further optimization.
■ RECOGNITION ELEMENT
There are broadly four types of recognition element used in
protein switches; small molecules, peptides, antibodies, and
binding proteins. Their purpose is to bind the target analyte
with appropriate selectivity over other molecules in the
biological matrix and with sufficient affinity to achieve the
desired assay sensitivity and range. It is imperative that these
qualities are optimal, to prevent the recognition element
limiting performance. Despite this, their affinity (Kd) is often
not stated, and only a few studies describe the correlation with
protein switch performance.31,32 Studies into the effect of
binding kinetics (kon, koff) may also prove insightful, to guide
future designs toward desired properties.
Small molecule recognition elements are limited to known
examples and must be conjugated to the sensor, which
complicates development and manufacture.33,34 Peptides are
more easily incorporated within the protein switch amino acid
sequence, including cleavage sites for proteases35−37 and linear
epitopes for antibody analytes.25,32,38−40 Linear epitopes are
often unavailable, but the scope can be broadened with
mimotopes and meditopes, which are disulfide linked cyclic
peptides selected by phage display, though still only for
antibody analytes.31,40 So, while small molecules and peptides
are useful for certain applications, neither offer the wide
analyte scope required for a general, modular protein switch
format.
Antibodies are by far the most common recognition element
used in ELISAs and LFDs, due to well-established develop-
ment processes and an enormous existing selection for varied
analytes. The ability to easily utilize this vast source of “off-the-
shelf” recognition elements within protein switches would
improve the scope and uptake of the technology. Whole
antibodies have only rarely been used for in vitro protein
switches,41 but in the new commercially available Lumit
immunoassay, antibodies are linked to each half of a proximity
protein switch.42 Attachment is via chemical modification of
the antibodies with synthetic ligands that bind a self-labeling
protein tag (HaloTag) on the reporter fragments.42 This offers
the potential to bring the technology into more mainstream
research use, as new assays can be developed by simple
exchange of commercially available antibodies. However, the
combination of HaloTag and the antibody makes the
recognition element extremely bulky and unsuitable for
switches where geometry and orientation are important.
Smaller antibody fragments, including Fab, VH/VL, and
particularly single domain antibodies like VHH, simplify the
geometric requirements for a functional switching mechanism,
and their genetic fusion to protein switches also streamlines
manufacture.29,43−47 The need to know the antibody sequence
prohibits use of polyclonal, hybridoma-derived monoclonal
and many commercial antibodies, but there are nonetheless
robust discovery methods for antibody fragments, so diagnostic
development is not restricted if time and budget allow.
Nature does provide alternative binding proteins to
antibodies, such as periplasmic binding proteins, but they are
limited to known examples and have only been used in protein
Figure 1. Schematic outline of (A) ELISA immunoassay with separate “capture” and “reporter” reagents, requiring multiple immobilization and
wash steps. (B) Lateral flow device immobilizes the “capture” reagent on a test line and free “reporter” reagent on a pad, with binding and washing
achieved by flow along the strip. (C) Protein switch combines “capture” and “reporter” elements at the molecular level and directly transduces
analyte binding to a signal in a “mix-and-read” assay.
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switches targeting certain small molecules.26,29,45,48,49 The
scope can be broadened using antibody mimetic non-
immunoglobulin binding proteins that consist of a scaffold
and variable peptide regions.50,51 They are selected with high
affinity and specificity for new analytes by display methods, so
development is quick and straightforward.50,51 Counter-
selection against competing molecules and affinity maturation
can be used to further increase specificity and affinity.52,53 Such
proteins are also small, nonglycosylated, and cysteine-free,50,51
so within protein switches they maintain the geometric benefits
of antibody fragments while being easier to recombinantly
manufacture. This makes them particularly attractive recog-
nition elements and many, including Affimers, DARPINS, and
monobodies, have been successfully utilized in protein switch
sensors for varied analytes.30,44,54,55
In pursuit of a general, modular protein switch format, it is
clearly advantageous to use selectable recognition elements
that can be developed to the appropriate affinity and selectivity
for wide ranging analytes. However, the current two-step
development process to select binders and then optimize their
insertion into a protein switch can be laborious. A binder or
binding pair selected as optimal using techniques such as
ELISA or SPR is not necessarily optimal within the protein
switch; for example, that with the highest affinity may not bind
the target with the best geometry for switch functionality. The
switch may then need to be optimized around it, which
complicates development. It would be more efficient if the
protein switch had variable binding regions and could be
selected from a large library directly based on switch
performance. Establishing selection methods may prove
difficult, but even an initial display-based screen followed by
medium-throughput activity screening of a focused library
would enable easier selection of functional switches. Small
steps toward this have been made with selection of
nonoverlapping binding pairs for proximity switches.44 Binders
which themselves undergo a conformational change have been
developed by fusion of selectable binding proteins in clamp-
like structures,56,57 but direct selection of a switching sensor is
yet to be achieved.
■ REPORTER
The purpose of a reporter is to rapidly generate a signal that
can be measured by a point-of-need compatible detector, with
appropriate sensitivity and range in the biological matrix.
Initially, many protein switches had fluorescent protein or dye
reporters,48,55,58 but sensitivity was limited by the lowest
measurable fluorescent probe concentration, typically nano-
molar, and there were issues with background autofluorescence
in biological matrices.59 They have thus been superseded by
enzymatic reporters that enhance sensitivity by signal
amplification, as in ELISAs. Despite enormous possibilities,
the same set of reporter enzymes encompassing proteases,37,60
β-lactamase,30,41,49,54 glucose dehydrogenase,26,29,35,45,61 and
luciferases27,31−34,36,40,43,44,47,62−64 are repeatedly used in
protein switches, perhaps due to their history as reporters in
other assays and the ease of recombinant production.
Dependent on the enzyme and substrate, there are four key
formats: colorimetric, fluorometric, luminescent, and electro-
chemical.
Colorimetric assays have low sensitivity, limited by the
extinction coefficient of the colored product, and poor range
due to difficulties in measuring high absorbances.65 Fluo-
rescence from products of a fluorometric assay can be
measured more sensitively and to very high readings compared
to absorbance, so the range is greatly improved.65 Never-
theless, there are issues with background autofluorescence.65
Protease and β-lactamase (BLA) reporters can use either
format depending on the synthetic substrate used.65 Protease
reporters are generally slow with assay time scales on the order
of hours, so they are unsuitable for rapid diagnostics.37,60 BLA
is faster with assays taking minutes but is significantly inhibited
in serum, which hinders its applicability to many clinical
applications.30
Figure 2. Schematic outline of protein switch designs. (Left) Proximity switches are activated by colocalization of components. (Middle) Domain
inserted allosteric switches are activated by conformational change. (Right) Modular allosteric switches are activated by conformational change at
linker regions.
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Luciferases are bioluminescent enzymes which emit light
upon substrate turnover. They are particularly promising
reporters due to their brightness and the fact that no incident
light source is required.66 There is no background auto-
fluorescence, so the bright glow is against a dark background,
enhancing sensitivity relative to fluorometric methods.66 The
range is also excellent as emitted light can be measured over
many orders of magnitude. Even a simple camera can be used
for detection, which is compatible with “point-of-need”
use.27,40 The engineered luciferase Nanoluc is the most
promising and widely used luciferase within sensor pro-
teins.25,27,31−34,38,40,43,44,47,62,66 It is small, highly stable, and
recombinantly produced,67 so it works well in a protein switch
fusion.66 It is brighter than other luciferases, which enhances
sensitivity, and its “glow” luminescence provides a sustained
signal, which simplifies measurement.67,68 A disadvantage is its
low emission wavelength (∼460 nm), which is readily
absorbed by biological matrices.66 Although this has been
somewhat overcome by the use of thin layers with low path
lengths, dilutions can still be required, which reduces
sensitivity.25,27,38,43 Matrix absorption is also reduced at higher
wavelengths, and red-shifted Nanoluc variants warrant further
investigation in sensor proteins.36,69−72 Other enzymes with
chemiluminescent substrates could expand the scope of
luminescent reporters66 but are yet to be explored in protein
switches.
Electrochemical reporters generate an electrical signal which
is easier to integrate into a cheap, miniaturized, electronic
detection device than optical systems and also overcomes the
need for transparent samples.73 This makes them particularly
attractive for point-of-care sensors, as evidenced by the success
of the electrochemical glucometer for diabetes management.74
Reporters that tap into this established technology have been
used in protein switches. Trehalase reporters generate glucose
so activity can be indirectly measured with a glucometer,
although background glucose in the biological matrix
complicates measurements.39,75,76 This is avoided if glucose
dehydrogenase (GDH) is itself used as a reporter, with a
saturating concentration of glucose substrate. GDH is well
developed and offers advantages in respect to its ease of
manufacture, high stability, turnover rate, and functionality in
biological matrices.26,29,35,45,61 Nevertheless, detection of
glucose oxidation by GDH protein switches has largely been
done colorimetrically, and sensitivity is very low when
measured electrochemically with a glucometer.26,29,35,45,61
Standard glucometers are set up to measure turnover by fully
active GDH, and adaptations are needed to improve sensitivity
for protein-switch measurements. Redox enzyme reporters like
GDH oxidize or reduce substrates, and this electron transfer
must be interfaced with the electrode for measurement as an
amperometric signal.77 In a standard glucometer, this is done
inefficiently by diffusion of redox mediators, but sensitivity is
improved by enzyme attachment to the electrode for direct
electron transfer.77 This also reduces interfering reactions, and
work is underway to interface GDH protein switches in this
way.35,78 Nevertheless, enzyme attachment in the correct
orientation for electron transfer can be a significant
challenge.79
Aside from GDH, there are a plethora of other redox
enzymes that could be explored as reporters, should their
operating potential be in a window free from background
matrix signals. Further to this, enzymes that change the redox
activity of their substrate (e.g., alkaline phosphatase with p-
NPP and β-galactosidase with PAPG) have been used for
electrochemical ELISAs and should be explored, as the product
can be accumulated and potentially redox-cycled to enhance
sensitivity.80−82 Overall, electrochemical reporters are an
underexplored tool within protein switches and further work
to study the sensitivity, range, and other crucial performance
characteristics of such systems would be insightful. The lack of
development to date may be due to the added complication of
interfacing the assay with an electrode, so future work should
be directed here.
■ SWITCHING MECHANISM
The purpose of the switching mechanism is to transduce
analyte binding at the recognition element into a signal change
at the reporter. The mechanism should minimize background
activity and maximize recovered activity with the analyte, to
ensure maximal signal change between the “off” and “on” states
(response dynamic range). It should also be functional for
wide-ranging analytes if a general, modular format is to be
achieved. Mechanisms are based on either two-component
proximity switches or one-component allosteric switches, with
domain inserted or modular designs (Figure 2).14
Proximity Switches. In proximity switches, analyte
binding induces colocalization of sensor components, which
results in a change in response (Figure 2). The most common
approach is split-enzyme complementation, in which an
enzyme is split into two inactive fragments, usually directly
but sometimes via mutations at a dimerization inter-
face.39,41,44−47,75,83 Each fragment is attached to recognition
elements that bind nonoverlapping epitopes on the analyte,
such that binding colocalizes the fragments and induces
reconstitution of the active enzyme.39,41,44−47,75,83 This
approach is insensitive to the exact geometry of the analyte
and binding domains, so long as linkers between the binder
and fragment are sufficient. Once colocalized, the high effective
concentration and residual affinity between fragments should
drive reconstitution, regardless of exact orientations. A split-
GDH showed the potential generality of such systems, with the
same design able to detect small molecules, proteins, and
proteases by simple exchange of recognition elements.45
Nevertheless, split-enzyme fragments can be unstable and
difficult to produce in vitro.45,83,84 Reconstituted activity can be
a fraction of the wild-type enzyme, and high residual affinity
between fragments causes background complementation,
which reduces the sensitivity and dynamic range of the
reporter response.45−47,83 A big problem with two-component
systems is that they are concentration driven, so dependent on
the absolute and relative component concentrations.26,59 To
prevent background complementation, fragment concentra-
tions must be well below the residual binding Kd, but this limits
the analyte concentration range that can be measured. Also, as
recognition elements are on two separate components, there
are no avidity effects to increase affinity, so each binder must
have sufficient affinity to achieve the required sensitivity. A
final consideration is that at high analyte concentrations, a
“Hook” effect can be observed, where instead of two
recognition elements binding one analyte to colocalize sensor
components, the analyte binds to each separately and reduces
the response. This can be overcome by control of the
component concentration or use of co-operative binders.
Protein engineering to overcome split-enzyme deficiencies is
a significant task but worth the time investment because once a
particular system is optimized it can form a modular format
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that is repeatedly used. Engineering of the NanoLuc reporter
into the NanoBit split-enzyme system is an excellent
example.24 Circularly permutated NanoLuc variants with
cleavable linkers were screened to identify a suitable dissection
site, yielding a small and large fragment with a proximity
constraint for activity.24 The larger polypeptide fragment
underwent two rounds of mutagenesis for stabilization and to
increase reconstituted activity to 37% of NanoLuc itself.24 The
smaller peptide fragment was separately mutated to reduce
residual affinity to Kd = 190 μM and diminish background
complementation, even at micromolar fragment concentra-
tions.24 The NanoBit system was linked to antibodies to form
the basis of the recent Lumit cell-lysate immunoassay.42 To
utilize NanoBit for diagnostic assays, both Dixon et al. and
Ohmuro-Matsuyama et al. further split the system, to give a
polypeptide and two peptide fragments.44,47 The two small
peptide fragments could be produced more easily in fusion
with recognition elements and the polypeptide could be held at
a separately high concentration in the assay.44,47 The sensitivity
(pM), response dynamic range (up to 100 000%), and analyte
linear range (>3 orders of magnitude) of these systems are
superior to other in vitro split-enzyme assays.39,41,44−47,75,83
These qualities are a testament to the engineering effort that
enabled low background complementation and high lumines-
cent activity recovery. Nevertheless, tests were in a maximum
5% serum matrix, and use as a general format for wide ranging
analytes is yet to be shown.
Domain Inserted Allosteric Switches. Allosteric
switches based on domain insertion involve fusion of the
recognition and reporter domains such that they are
allosterically coupled, and binding at the recognition element
is transduced into a change in activity of the reporter (Figure
2). Ascertaining a tolerant insertion site for optimal allostery
between the domains is challenging.14 Recently, this has been
done by rational design, as in the case of calmodulin insertion
into GDH,61 and by screening of random insertions of
circularly permutated BLA into periplasmic binding proteins.49
Upon analyte binding, both calmodulin and periplasmic
binding proteins undergo a conformational change, which is
conferred into a change in conformation and activity of the
inserted reporter domain.49,61 However, such structure-switch-
ing binding proteins are limited, and generating allostery is
more challenging with common recognition elements that
undergo minimal conformational change. When BLA was
randomly inserted into DARPIN and monobody binding
proteins, allosteric switches could be selected.54 However,
binding affinity was reduced in the fusion, and micromolar
analyte concentrations were required to drive a switching
effect.54 Further, only one of four attempts to target new
analytes by exchange of binding proteins was successful,
highlighting the lack of generality to the approach.54 A solution
may lie in the development of selectable structure-switching
binding proteins, such that allosteric coupling to the reporter is
more reliable. Affinity clamps are selectable bidomain proteins,
which enclose around peptides and have been used to generate
peptide-responsive allosteric switches.29,56,85 Building on this,
Leǵer et al. fused selectable monomers into bidomain proteins
that open up to bind protein analytes.57 However, it remains to
be seen if they can target varied analytes and be allosterically
coupled to reporter enzymes.
An alternative approach is to establish an allosteric switch
and then integrate it into a higher order architecture to target
varied analytes. Alexandrov and co-workers used structure-
guided design to insert calmodulin into GDH (CaM-GDH) at
a site where cofactor interacting residues are displaced (Figure
3A).29 Binding of calmodulin binding peptide (CaM-BP)
induces a contraction that is allosterically coupled to GDH and
restores cofactor interactions, recovering 50% of wild-type
activity. CaM-GDH and CaM-BP were then fused to
recognition elements, so analyte binding drives colocalization
for activity recovery (Figure 3B). A range of small molecules
and proteins was successfully targeted by exchanging
recognition elements (binding proteins, VHH), so integration
of the proximity mechanism gives a modular format
independent of exact binding orientations. However, low
affinity CaM-BP was used to minimize background activation
and the truncated peptide did not induce the same structure
change in CaM, reducing activity recovery. Concentrations of
the two-component sensor also had to be lower than the
residual CaM-BP binding Kd, which limited the analyte range
that could be measured (∼1−10 nM for rapamycin). To
overcome this, native CaM-BP was “caged” with low affinity
CaM, giving a kinetic and thermodynamic barrier to
background activation (Figure 3C).26 At micromolar compo-
nent concentrations, the “uncaged” sensor was fully self-
activated, whereas the “caged” sensor had low background
activation and so was analyte responsive.26 Rapamycin was
measurable over ∼10−1000 nM, with a response dynamic
Figure 3. Allosteric GDH switches designed by Alexndrov and co-workers.26 (A) Core design. (B) Higher order proximity switch architecture. (C)
“Caged” system. Reprinted with permission from ref 26. Copyright 2020 American Chemical Society.
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range of ∼1300%, but this was dependent on the two-
component concentrations.26 Progress toward optimizing the
CaM-BP/CaM “cage” system was made and may lead to
further improvements in sensor performance.26 Fluorescent
protein and NanoLuc based switches could be similarly
constructed but unlike the “uncaged” sensors performance in
biological matrices was not verified.26,29
Modular Allosteric Switches. Modular allosteric switches
comprise structurally distinct recognition and reporter
domains, with conformational change limited to linker regions
and induced by mutually exclusive binding interactions (Figure
2).14 They are generally based on modulation of an enzyme−
inhibitor interaction or bioluminescent resonant energy
transfer (BRET).27,30−32,34,40,43,62,85,86 Unlike domain-inserted
switches, the structurally distinct recognition element should
maintain its affinity and need not be structure-switching, so
common ones can be used interchangeably. The intact reporter
domain should also retain its full activity and stability, unlike
split and domain-inserted reporters that can be structurally
compromised and suffer weaker activity recovery. One-
component modular allosteric switches are less concentration
dependent than two-component systems but binding geometry
can be more critical to ensure disruption of the competing
interaction.
Autoinhibited enzyme switches comprise an enzyme
tethered to an inhibitor via a linker containing recognition
elements.14 Analyte binding induces a linker conformational
change, which disrupts the enzyme−inhibitor interaction and
restores activity.14 In a recent example, BLA was tethered to its
inhibitor protein (BLIP) via a flexible linker containing two
Affimer binding proteins.30 This gives an avidity effect, and
with anti-hCRP Affimers of Kd = 12 nM, hCRP was
measurable over 30 pM to 30 nM.30 As in a previous switch,
the BLA-BLIP interaction was weakened to enable disruption,
but this increases background activity and is a limiting factor to
sensitivity.30,86 Nevertheless, 83% of wild-type BLA activity
was regained upon activation, and the response dynamic range
was up to 1200%.30 Previous autoinhibited switches targeting
peptides and antibodies have been reliant on the exact
geometries of those analytes.85,86 The use of selectable Affimer
binding proteins and an optimized flexible linker enabled a
range of proteins to be targeted (antibody, hexameric protein,
virus).30 However, these large multimeric proteins can induce
significant linker conformational change, and it remains to be
seen if monomeric proteins or small molecules can be targeted
without significant linker redesign for each analyte. Further-
more, only a 1% serum matrix could be used,30 and better
performing electrochemical and luminescent reporters are yet
to be explored, perhaps due to the difficulty in generating
appropriate inhibition domains.
BRET sensors are based on a modulation of distance and
thus resonant energy transfer between a luciferase and
fluorophore.66 Merkx and co-workers introduced LUMABS
(LUMinescent AntiBody Sensor), in which blue light emitting
NanoLuc and linked mNeonGreen fluorescent protein are held
close together by helper domains (Figure 4A).32 Antibody
binding to two recognition elements (epitopes, cyclic peptides,
or small molecules) extends the linker between them and
disrupts the helper domain interaction.31−33 The distance
between NanoLuc and mNeonGreen increases, which
decreases BRET and the ratio of green/blue emitted
light.31−33 Such ratiometric measurements are independent
of sensor concentration and matrix effects on absolute signal
intensity, and so are reproducible.31−33 The maximal response
dynamic range was ∼300%, limited by how close the domains
are able to get in the “closed” state and the large background
NanoLuc signal at mNeonGreen’s emission wavelength.33 The
recognition elements need sufficient affinity to overcome the
helper domain interaction, but use of two gives an avidity
effect, and with HIVp17 epitopes of Kd = 42 nM, the anti-
HIVp17 antibody was measurable over 10−1000 pM.32 The
sensors were also functional in undiluted plasma but with light
intensity and the sensitivity reduced 10-fold.32 LUMABS are
restricted to antibody analytes as they depend on the Y-shaped
presentation of two antigen binding domains at a sufficient
distance to induce a measurable change in BRET.31−33 Small
molecules have been targeted but in a competitive format,
functional only at low millimolar analyte concentrations.33 An
alternative NB-LUMABS sensor is based on intramolecular
split NanoLuc complementation and BRET to a directly
attached red fluorescent dye.40 In the “closed” state, NanoLuc
and the fluorophore are closer, and thus BRET is more
efficient than when using bulky fluorescent protein and helper
domains.40 The background NanoLuc signal is also lower at
the red fluorophore emission wavelength, which improves the
response dynamic range (∼500%) and sensitivity (low pM).40
Fluorophores with large differences between their excitation
and emission wavelengths may be useful, so excitation overlaps
well with NanoLuc emission for efficient BRET, but emission
is at red-shifted wavelengths with a low background from
NanoLuc.
Figure 4. BRET-based modular allosteric switches. (A) LUMABS developed by Merkx and co-workers.32 Reprinted with permission from ref 32.
Copyright 2016 American Chemical Society. (B) LUCIDs developed by Johnsson and co-workers.43 Reprinted with permission from ref 43.
Copyright 2017 Wiley.
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Johnsson and co-workers developed LUCIDs (LUCiferase-
based Indicators of Drugs), which comprise a receptor protein,
NanoLuc and SNAP-tag labeled with a red-emitting
fluorophore and synthetic ligand analogue of the target drug
(Figure 4B).43,87 An intramolecular interaction between the
ligand analogue and receptor protein is disrupted by target
drug binding, which increases the distance between NanoLuc
and the fluorophore.43,87 The reduction in BRET efficiency is
reproducibly measured as a ratiometric change in red/blue
emitted light.43,87 Antibody fragments (Fabs) have a common
3D structure, so they can target new drugs without an
optimization of sensor geometry for efficient BRET.43
However, the synthetic ligand/Fab interaction must be
weakened, so that the free drug can compete and be measured
over a clinically relevant range.43 This requires mutation and
synthetic ligand optimization for each new sensor, based on
structural knowledge that may not always be available.43 It
does enable sensor tuning, and for example, methotrexate is
measurable over 53 nM to 5 μM or 1−130 μM using
appropriately tuned sensors.43 The response dynamic range is
up to 2155%, due to the close proximity of NanoLuc and
fluorophore in the “closed” state and their distance in the
“open” state, enforced by a long rigid proline linker (Pro30).43
Importantly, LUCIDs are also functional in 50% serum and
10% whole blood.43 Similar sensors have been optimized to
transition from an “open” to “closed” state upon binding
NADPH or NAD+, which enables indirect measurement of
many associated metabolites and enzymes via production of
these cofactors.27,62 Another similar sensor has an additional
ligand that binds protein, driving a transition from the “closed”
to “open” state by steric hindrance.34 Streptavidin and
dihydrofolate reductase have been targeted, but it remains to
be seen if this is a generally applicable strategy.34 Resonant
energy transfer has an inverse sixth-power distance depend-
ence, so designing sensor formats that are independent of
target geometry is challenging and an important area for
research.
■ ASSAY VALIDATION
New protein switch designs are often only analyzed in terms of
a few qualities and are rarely rigorously assessed against all the
appropriate performance criteria. More thorough and com-
parable analysis between sensors would make the quality and
potential of new designs much clearer, and better highlight
areas for improvement. Assay speed is absolutely critical in the
context of the test application; for example, in many countries,
doctors’ consultations last 10−15 min, so any test used at this
point in the care pathway must be significantly faster. Total
assay time is perhaps the only universally reported quality, and
most protein switches operate on multiminute time scales,
which compares unfavorably with blood glucose monitors that
give a response in seconds. In terms of sensitivity, the limit of
detection (LOD) is often not explicitly calculated, and where it
is, different methods are used. The often used meanblank +
3σblank method only accounts for variability in blank measure-
ments, and we feel that stricter definitions which also account
for variability in test measurements are more reliable.88 Target
selectivity is sometimes studied; for example, specificity for a
certain IgG over others has been tested for various antibody
sensors,25,30,31,38 but such assessments could be more widely
adopted. Reproducibility is extremely important if an assay is
to ultimately be used for real-world analysis, but some studies
do not even include repeat measurements. The standard
deviation of three repeats is often reported, but large scale
analysis of intra- and interassay coefficients of variation is
rare.27 Batch-to-batch reproducibility is also crucial to ensure
consistency between lots, but this is also only rarely
investigated.25,30,38 The analyte range over which a protein
switch assay is functional is usually reported, but rigorous
calculations of the upper and lower limits of quantification
alongside the accuracy and precision of measurements in
between are omitted. Performance in biological matrices
should always be thoroughly studied but is often lacking.
Detection of an analyte spiked in a certain percentage of matrix
is often shown, but data on the exact effect of this matrix
compared to buffer are frequently absent. Studies are usually
limited to assessment of the analytical accuracy with spiked
samples and a comparison of measurements between the
protein switch and a “gold standard” assay.27,29,30,62,76
Evaluation of the diagnostic accuracy in patient or other
real-world samples is infrequently completed but is absolutely
critical to understand the utility of the assay. In terms of
practical considerations, although shelf life is frequently
studied,25,27,29,30,38,43,45,62 other factors including costs and
ease of manufacture are largely ignored, despite being vital for
real-world uptake.
While comprehensive analysis of all these parameters may
not always be appropriate, we do feel that more consistent
reporting standards would aid comparison between protein
switches and guide further improvements. Furthermore,
translation of protein switch assays into real-world use is
reliant on extensive validation, and it will not be adopted until
this is done. For well-developed protein switches, the next
important step is thorough analytical validation of assay
performance to regulatory standards, for example, the U.S.
FDA criteria for bioanalytical method validation.89 Only then
will such assays show their potential to be used in routine
diagnostic use. For clinical diagnostics, further evaluations are
then needed to determine how the test works in patient
samples (the diagnostic accuracy) and in a clinical setting to
improve patient care (the clinical utility). Co-design of devices,
with the end-user involved at an earlier stage of the design
process, may be a means to improve the rate at which assays
are pulled through to these evaluations.
■ DEVICES
While the discussed protein switches offer promise, the assays
still require liquid handling steps (e.g., pipetting) and often use
laboratory detection devices (e.g., plate readers), prohibiting
direct use at the point-of-care or in-field. Most research is
focused on switch design, but methods to fully integrate such
assays into a user-friendly point-of-need device are urgently
required if practical implementation of the technology is to be
achieved. Device integration can also improve some aspects of
assay performance, including speed, sample volume require-
ments, functionality in biological matrices, and ability to
multiplex. Existing technology for point-of-care immunoassays,
including chip- and paper-based microfluidic devices, can be
tapped into, and integration with no-wash protein switch
assays should, in fact, be easier.90−92 A fully device-integrated
electrochemical protein switch assay has yet to be achieved,
largely due to the described complexities of interfacing the
assay and electrode, while preventing fouling by the biological
matrix. Electrochemical protein switches have been attached to
screen-printed gold electrodes via covalent linkers and carbon
fiber electrodes via graphene nanosheets.35,78 Other interfacing
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strategies from biosensors,93−95 or even complementary
technology such as biofuel cells,96 should be explored. Once
interfacing is optimized, devices encompassing liquid handling
and detection can be developed from existing electrochemical
point-of-care technology, such as the glucometer.97,98 Device
integration is further developed for BRET sensors, and recent
microfluidic approaches have shown great potential.25,36,38
Weihs et al. have integrated a BRET-switch assay into a
microfluidic glass chip comprising a chaotic mixer for the
sensor, substrate and sample mixing, an incubation channel,
and a narrow chamber for optical detection.36 This minimizes
luminescent signal absorption for measurements in a 10%
serum matrix, and the total channel volume of 23.6 μL allows
for low sample volumes.36 The chip is used in a device
containing syringe pumps for sample flow, a heat-block for
temperature control, and microphotomultiplier tubes for signal
detection.36 While this does enable a fast (5 min), low cost
assay, some liquid handling is still required, and the 6.5 kg
device affords poor portability.36 Tenda et al. describe a
smaller, fully integrated microfluidic paper-based analytical
device (μPAD) for BRET-switch assays.38 Whole blood is
processed by a plasma separation membrane, which flows by
capillary action into paper layers impregnated with the
substrate and then the LUMAB sensor.38 The bioluminescent
signal is simply detected by a camera.38 This design has
recently been improved by using a 3D-printed attachment to a
smart-phone camera alongside a microfluidic thread-based
analytical device (μTAD; Figure 5).25 The substrate and
sensor protein are instead impregnated on intertwined threads,
which reduces the dead volume, reducing assay times and
sample volume requirements.25 In fact, in just 5 min, 5−15 μL
of whole blood can be tested without sample volume
dependency, making it compatible with a finger prick of
blood.25 The design enabled up to 6-plex detection on
different zones of the device,25 which is an important
development as no protein switch in itself offers multiplex
detection. Clinical diagnoses often require laboratory analysis
of panels of analytes, and efficient uptake of point-of-care
alternatives relies on incorporation of all of the desired
analysis.99 The multiplex device was also stable for a month,
could be reproducibly fabricated and is cheap to produce for
low-resource settings.25 Crucially, it was compatible with an
alternative NB-LUMABS sensor, so it has the potential to be
used with other BRET protein switches without device
redesign.25 A plethora of other microfluidic technologies
could be explored, to find optimal solutions to drive the
much needed translation of protein switch assays into practical
use. This is arguably now the most pressing area of research, as
no assay will ever actually be used at the point of need, unless
fully integrated into an easy-to-use device.
■ OPPORTUNITIES
Should the described challenges be overcome, the oppor-
tunities for protein switch technology in quantitative point-of-
need diagnostics is vast. Protein switches have thus far been
largely developed for healthcare applications, where there is
great potential to improve disease prediction, speed up
diagnosis, and monitor drug dosing, to give better patient
outcomes. There are wide opportunities for protein switch
antibody tests: those developed for infectious disease serology
could be widened to autoimmune, allergy, and broader
immunology applications,25,32,38,40,59 and those for therapeutic
drug monitoring can guide dosing in the ever-growing
biologics market.25,30,31,40 Small molecule tests have also
been developed for drug monitoring,26,43 as well as
metabolic27,62 and disease biomarker assays.33,100 Tests for a
range of proteins have also been reported, and the scope
expands as new biomarkers are discovered.29,30,41,44 Human
health applications dominate the literature, but the significant
opportunities for quantitative on-site tests should be explored
in broader sectors. Some protein switch assays have been
developed for food standards,63 agricultural disease monitor-
ing,30 and veterinary immunology applications,75,76 but there
are much wider prospects in these settings and others,
Figure 5. Antibody detection in whole blood using LUMABS on a μTAD developed by Citterio and co-workers.25 Reprinted with permission from
ref 25. Copyright 2020 American Chemical Society.
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including environmental monitoring, illicit drug detection, and
sports medicine.1
■ CONCLUSION
Engineered protein switches directly transduce analyte binding
into a detectable signal in a simple, wash-free, homogeneous
assay format. They comprise a recognition element, reporter,
and switching mechanism, which all impact on performance
according to their designs. In terms of recognition elements,
antibody fragments, and selectable nonimmunoglobulin bind-
ing proteins offer the widest target scope. Luminescent
reporters afford high sensitivity and range, while the potential
of electrochemical reporters for simple integration into
electronic devices is underexplored. Domain inserted allosteric
switches are challenging to develop for new targets and have
been largely superseded by more modular approaches. Two-
component proximity switches are largely independent of
target binding geometry but can suffer concentration depend-
ent background activation. One-component modular allosteric
switches are less concentration dependent, but exact binding
geometries are more important. While such comparisons
between approaches can be made, academic studies making
systematic changes to a certain design aspect while keeping
others constant would give a much clearer perspective on
design-performance relationships and guide optimization of
future designs. Crucially, protein switch signaling in nature
operates down to the millisecond time scale, and more studies
should evaluate the rate limiting steps of synthetic protein
switch responses to guide assay times down from the current
multiminute time frames.26 The dynamic range of protein
switch assays is highly variable and is another key area where
the design-performance relationship must be better under-
stood. Recent efforts toward modular switches that can target
new analytes without redesign are crucial to ensure a fast and
robust development process. In the future, high-throughput,
computational, and de novo design approaches may guide
more efficient design and development.101,102
Protein switches could underpin quantitative point-of-need
diagnostics needed across wide applications to improve access,
costs, and speed compared to laboratory assays. Yet despite
this potential, they are yet to be established in routine
diagnostic use. Practical implementation can only be achieved
through integration into user-friendly devices and thorough
validation of the assay. It is particularly crucial to compare the
protein switch to a “gold standard” laboratory assay in its
ability to measure analytes in clinical or real-world samples.
While design of novel protein switches with improved
performance characteristics is of course important to drive
progress, it is crucial to remember that they cannot be
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■ VOCABULARY
Allostery, the process by which proteins translate the binding
of an effector molecule at one site to another functional site,
thereby regulating activity; Bioluminescence, a specific form of
chemiluminescence observed in living organisms, in which
light is emitted upon turnover of a luciferin substrate by a
luciferase enzyme. The reaction involves an excited state
intermediate, which decays to a ground state via emission of
light energy; Electrochemical, chemical reactions that involve
the transfer of electrons and can be measured as an electrical
signal; Immunoassay, a biochemical test that detects or
quantifies an analyte in solution, using an antibody or antigen
binding reagent; Microfluidics, the manipulation and control of
fluids that are constrained to sub-millimeter channels
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